You are here

  • Home
  • Archive
  • Volume 3, Issue 1
  • Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis

Article metrics

Article menu

Download PDFPDF

XML
Inflammatory bowel disease
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis

 

Online download statistics by month:

Online download statistics by month: July 2017 to March 2024

AbstractFullPdf
Jul 2017414113
Aug 2017464722
Sep 2017313111
Oct 2017393918
Nov 2017505017
Dec 2017535326
Jan 2018404014
Feb 2018474717
Mar 2018787224
Apr 2018696940
May 2018686923
Jun 2018636318
Jul 201812011821
Aug 201813113129
Sep 201812612525
Oct 201814014029
Nov 201813313317
Dec 2018616120
Jan 2019646221
Feb 2019747425
Mar 2019818132
Apr 2019525215
May 2019777627
Jun 2019535318
Jul 2019646517
Aug 2019454418
Sep 2019403911
Oct 2019697021
Nov 2019282819
Dec 2019373519
Jan 2020545319
Feb 2020929116
Mar 2020606033
Apr 2020525231
May 2020585919
Jun 2020454115
Jul 2020595126
Aug 2020524230
Sep 2020554820
Oct 2020756717
Nov 2020695928
Dec 2020746916
Jan 2021817324
Feb 2021797520
Mar 20211089622
Apr 2021897914
May 2021747119
Jun 2021514918
Jul 2021605316
Aug 2021827621
Sep 2021848317
Oct 202111811132
Nov 20211029632
Dec 2021716237
Jan 20221029629
Feb 2022939014
Mar 202210410320
Apr 2022757421
May 2022606018
Jun 2022757019
Jul 202211710815
Aug 20221471478
Sep 202214413415
Oct 202214714918
Nov 202215215323
Dec 2022979613
Jan 202322021322
Feb 202313913416
Mar 20231089519
Apr 20231049922
May 202313313111
Jun 202314013714
Jul 2023959915
Aug 2023999315
Sep 2023908916
Oct 2023929014
Nov 202311711018
Dec 202390907
Jan 202426268
Feb 2024666718
Mar 202415114917
Total674765261614